Turning a corner on HIV neutralization?
HIV vaccine development has been hampered by the inability of conventional immunogens to elicit antibodies capable of neutralizing primary isolates of the virus. Recent studies using 'fusion-competent' immunogens that capture transitional intermediate structures of the functioning envelope protein suggest that this goal may now be achievable.
Nunberg
J H
JH
Montana Biotechnology Center, The University of Montana, Missoula, MT 59812, USA.
Follis
K E
KE
Trahey
M
M
LaCasse
R A
RA
D016915:AIDS Vaccines / Q000276:immunology*; D000818:Animals; D006678:HIV / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000276:immunology; D015658:HIV Infections / Q000517:prevention & control*; D006801:Humans; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D014614:Vaccines, Synthetic / Q000276:immunology*
D016915:AIDS Vaccines; D015699:HIV Envelope Protein gp120; C059762:HIV envelope protein gp120 (305-321); D010446:Peptide Fragments; D014614:Vaccines, Synthetic